For years, Sarah Cossar from South Australia lived with constant urgency and pelvic pain, waking up multiple times a night to wee, but she thought she just had a ‘small bladder’. After learning her ...

Bladder Control Problems? There May Be An App For That By Dennis Thompson HealthDay ReporterTHURSDAY, Sept. 18, 2025 (HealthDay News) — Having trouble with bladder control? There might be an app for ...

The U.S. Food and Drug Administration has approved Inlexzo (gemcitabine intravesical system) for the treatment of patients with certain types of bladder cancer. Specifically, Inlexzo is indicated for ...

Inlexzo is a new treatment for a type of bladder cancer in adults that hasn’t spread to the muscles and doesn’t respond to Bacillus Calmette-Guérin (BCG) therapy. It’s approved for treating non-muscle ...

Sept 10 (Reuters) - The U.S. Food and Drug Administration has approved Johnson & Johnson's (JNJ.N), opens new tab drug delivery system for a type of bladder cancer, offering a potential surgery-free ...

State laws and regulatory chaos are driving the country’s largest pharmacy chains to require prescriptions or hold back altogether unless a C.D.C. panel acts. By Maggie Astor and Dani Blum CVS and ...

Topline results from the IMvigor011 trial show that ctDNA-guided adjuvant atezolizumab improves survival in patients with MIBC. Adjuvant atezolizumab in patients who are ctDNA-positive after radical ...

This guide provides an overview of bladder cancer, from diagnosis to treatment, helping patients understand options, manage side effects, and plan care. A cancer diagnosis is a life-altering event ...

A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously ...

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

Matthew Herper covers medical innovation — both its promise and its perils. Pfizer said Tuesday that its antibody-drug conjugate Padcev extended survival when combined with the cancer immunotherapy ...